CLOVER HEALTH INVESTMENTS CO (CLOV)
US18914F1030 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to CLOV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.77. This target is 41.08% above the current price.
CLOV was analyzed by 10 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CLOV.
In the previous month the buy percentage consensus was at a similar level.
CLOV was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-17 | Craig-Hallum | Initiate | Buy |
| 2024-10-07 | UBS | Initiate | Neutral |
| 2023-08-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2023-03-06 | Canaccord Genuity | Maintains | Buy |
| 2023-03-06 | Credit Suisse | Maintains | Underperform |
| 2022-11-16 | Citigroup | Maintains | Neutral |
| 2022-11-08 | SVB Leerink | Maintains | Market Perform |
| 2022-08-09 | Credit Suisse | Maintains | Underperform |
| 2022-08-09 | Citigroup | Maintains | Neutral |
| 2022-05-10 | SVB Leerink | Maintains | Market Perform |
| 2022-02-25 | SVB Leerink | Maintains | Market Perform |
| 2022-02-02 | Cowen & Co. | Upgrade | Underperform -> Market Perform |
| 2022-02-02 | Canaccord Genuity | Initiate | Buy |
| 2022-01-19 | SVB Leerink | Initiate | Market Perform |
| 2022-01-07 | Credit Suisse | Downgrade | Neutral -> Underperform |
| 2021-11-15 | Credit Suisse | Maintains | Neutral |
| 2021-09-10 | Cowen & Co. | Initiate | Underperform |
| 2021-07-12 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-06-10 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2021-05-19 | Credit Suisse | Maintains | Neutral |
| 2021-05-17 | B of A Securities | Downgrade | Buy -> Neutral |
| 2021-03-09 | Credit Suisse | Initiate | Neutral |